Zhitong Finance App News, Colunbotai Biotech (06990.HK) announced that the company has received a clinical trial notice from the National Drug Administration (NMPA) Drug Evaluation Center (CDE) approving the application for clinical trial (IND) of the novel dual-loaded ADC drug SKB565 for the treatment of advanced solid tumors. This is the company's first dual-load antibody conjugate drug (ADC) to enter the clinical phase.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.